Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

WALTHAM, Mass., Dec. 19, 2023 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced…